Sugi Predict

Sugi Predict / Compounds / SCHEMBL1968373

SCHEMBL1968373

SCHEMBL1968373

CN1CCN(C(=O)OC(C)(C)C)CC1=O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ NR1H2 P55055 2/20 0.46
▸ ESR2 Q92731 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ P2RX7 Q99572 3/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ GPR119 Q8TDV5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5041300 0.90 MEN1 (0.46) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL3968708 0.85 USP2 (0.49) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL29136746 0.84 USP2 (0.43) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL25422301 0.84 USP2 (0.47) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL13244889 0.83 USP2 (0.46) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL14800964 0.82 USP2 (0.52) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL20812242 0.81 NR1H2 (0.45) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL3478731 0.81 NR1H2 (0.45) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL16419557 0.81 NR1H2 (0.46) USP2SMN1; SMN2NR1H2ESR2MAPT
SCHEMBL2673770 0.81 USP2 (0.42) USP2SMN1; SMN2NR1H2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117500786-A TEAD inhibitors 奥赖恩公司 2024-02-02 — — CN disclosed
WO-2023109909-A1 AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF 上海翊石医药科技有限公司 2023-06-22 — — WO disclosed
US-11660303-B2 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity KANCERA AB (SE) 2023-05-30 — — US disclosed
CN-109563092-B 2-phenylimidazo [4,5-B ] pyridin-7-amine derivatives useful as inhibitors of the activity of the mammalian tyrosine kinase ROR1 坎塞拉有限公司 2021-09-14 — — CN disclosed
CN-107098886-B Prazinone-containing quinazolinone PARP-1/2 inhibitor and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2020-07-14 — — CN disclosed
WO-2018086589-A1 1,5,7-TRI-SUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES 上海海雁医药科技有限公司 2018-05-17 — — WO disclosed
US-20180117041-A1 LIVER X RECEPTOR MODULATORS VITAE PHARMACEUTICALS, INC. 2018-05-03 — — US disclosed
EP-3309148-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS Bristol-Myers Squibb Company (US) 2018-04-18 — — EP disclosed
EP-2766346-B1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-03-29 — — EP disclosed
US-9192607-B2 Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-24 — — US disclosed
US-20040147521-A1 Compositions comprising zopiclone derivatives and methods of making and using the same ALTER DOMUS (US) LLC 2004-07-29 — — US disclosed
WO-2004037212-A2 COMPOSITIONS COMPRISING ZOPICLONE DERIVATIVES AND METHODS OF MAKING AND USING THE SAME SEPRACOR, INC. (US) 2004-05-06 — — WO disclosed
WO-2003066621-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS GLAXO GROUP LIMITED (GB) 2003-08-14 — — WO disclosed
EP-0882041-B1 PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2003-03-26 — — EP disclosed
US-6069145-A AGAINST ANTIBIOTIC RESISTANT BACTERIA ZENECA LIMITED (GB) 2000-05-30 — — US disclosed
EP-0882041-A1 PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS AstraZeneca AB (SE) 1998-12-09 — — EP disclosed
WO-1997027188-A1 PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ZENECA LIMITED (GB) 1997-07-31 — — WO disclosed
EP-0202048-B1 CARBAPENEM DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANKYO COMPANY LIMITED (JP) 1991-10-30 — — EP disclosed
US-4771046-A ANTIBIOTICS SANKYO COMPANY, LIMITED (JP) 1988-09-13 — — US disclosed
EP-0202048-A1 Carbapenem derivatives, their preparation, and pharmaceutical compositions containing them SANKYO COMPANY LIMITED (JP) 1986-11-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180117041-A1 LIVER X RECEPTOR MODULATORS SLC10A1, NR1H4, NR1H2 USP2 3252/4885SMN1; SMN2 3358/4885NR1H2 3/4885
US-20040147521-A1 Compositions comprising zopiclone derivatives and methods of making and using the same CYP51A1, CYP3A43, CYP4A11 USP2 4810/4885SMN1; SMN2 4512/4885NR1H2 62/4885
US-11660303-B2 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity ROR1, RORB, RORA USP2 4095/4885SMN1; SMN2 1506/4885NR1H2 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.